Welcome to our dedicated page for STRYKER SEC filings (Ticker: SYK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Stryker Corporation filings document the regulatory record of a New York Stock Exchange-listed medical technology issuer with operations in MedSurg, Neurotechnology and Orthopaedics. Its 8-K reports cover operating results, financial-condition updates, material events, Regulation FD disclosures and exhibits tied to company press releases.
The filing record also describes governance and capital-structure matters, including definitive proxy materials, annual-meeting votes, director elections, auditor ratification, executive-compensation votes, common stock and listed senior unsecured notes. Recent material-event filings include cybersecurity incident disclosures and amendments describing operational and reporting updates connected to Stryker's information technology environment.
STRYKER CORP (SYK) officer Dylan Bram Crotty, a Group President, reported selling 441 shares of common stock on 2026-08-21 at $328.605 per share. The sold shares were held indirectly through the Dylan B Crotty Trust. After this sale, the trust held 6,102 shares.
Crotty also reported separate holdings of 5,474 shares held directly, 1,509 shares held indirectly via a 401(k), and 313 shares each held indirectly for a daughter and a son.
STRYKER CORP (SYK) director Ronda E. Stryker reported open-market sales of 350,000 shares of common stock on August 18–19, 2026, through a revocable trust, at weighted average prices generally between $331.15 and $343.90 per share. After these transactions, she reports holdings of 12,177,521 shares indirectly via the L. Lee Stryker Trust, 37,600 shares indirectly via the 1988 William D. Johnston Trust, and 762 shares held directly.
STRYKER CORP (SYK) officer Debra King, VP and Chief Digital and Information Officer, reported selling 826 shares of common stock on 2026-08-18 in an open-market transaction at a weighted average price of $336.304 per share, with individual trade prices ranging from $336.255 to $336.304. Following this sale, she directly holds 6,210 shares of SYK common stock and indirectly holds 8 shares through a 401(k) plan.
STRYKER CORP (SYK) received a notice of proposed sale of restricted securities under Rule 144 for the account of Debra King. The filing covers 826 common shares, acquired through RSU vesting on 08/01/2026, with an aggregate market value of 277,786. Stryker common stock outstanding is reported as 383,573,046 shares, and the proposed sale is approximately dated 08/18/2026 on the NYSE, with UBS Financial Services Inc. acting as broker and attorney-in-fact signing on King’s behalf.
STRYKER CORP officer Kimberly Ann Montagnino, VP, Chief Communications Officer, had 155 shares of Common Stock withheld on August 1, 2026 to satisfy exercise-price or tax-liability obligations at $325.70 per share, leaving 1,717 shares held directly plus 33 shares held indirectly through a 401(k).
Debra King, VP and Chief Digital and Information Officer of Stryker Corp, had 533 common shares withheld at $325.7000 per share on 2026-08-01 to cover an exercise price or tax liability. After this code F disposition she holds 7036 shares directly and 8 shares indirectly via a 401(k).
Stryker Corp executive Robert S. Fletcher, VP and Chief Legal Officer, reported a disposition of 94 shares of common stock on 2026-08-01 to pay an exercise price or tax liability at $325.70 per share. After this withholding, he holds 10,488 shares directly and 184 shares indirectly through a 401(k). The transaction was not reported under a Rule 10b5-1 trading plan.
Stryker Corp executive M Kathryn Fink, VP and Chief HR Officer, reported an F-code tax- or exercise-related disposition of 111 common shares on August 1, 2026 at $325.70 per share. After this withholding, she directly holds 13,027 shares, including 129 acquired through the Employee Stock Purchase Plan as of June 30, 2026, plus 177 shares held via the 2023 Mary Fink Living Trust and 445 shares held via a 401K.
Stryker Corporation reported strong Q2 2026 results, with net sales of $ 6,589 versus $ 6,022 in 2025 and net earnings of $ 1,276, or $ 3.30 per diluted share. Gross profit margin improved to 68.3% and operating margin to 25.2%, helped by lower import tariffs and reduced inventory step-up amortization.
For the first six months of 2026, net sales were $ 12,609 and net earnings were $ 2,021, or $ 5.23 per diluted share. Adjusted net earnings per diluted share were $ 3.69 in Q2 and $ 6.29 year to date. Operating cash flow increased to $ 1,842, while total debt decreased to $ 14,942 after repaying $ 1,000 of senior notes. Stryker also completed the AVS acquisition for $ 435 in cash plus up to $ 400 in contingent milestone payments, adding a next-generation intravascular lithotripsy platform to its Peripheral Vascular business.